semaglutide mash targets molecular pathways beyond weight loss Novo Nordisk secures FDA approval

RETURN OF CARDIOMETABOLIC MARKERS: The HbA1c, the blood pressure, the cholesterol, the lipids - those markers might improve while on a GLP-1 weight loss protocol, but this meta-analysis found that these markers, in addition to 2/3 of lost weight, were regained after discontinuing GLP-1

[9] cGMP mandates that the quality assurance unit within the 503B outsourcing facility be autonomous

Hirsch IB

Evidence of increased RGC in patients receiving GLP-1RAs has been demonstrated both by endoscopy [68] and gastric ultrasound [911]

Second, oral Wegovy at the higher 25 mg dose has been approved in the US since December 2025